Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novavax

Missed BBBY? 10 'Meme Stocks' Are Next Gold Mines, Analysts Say

Chasing best-known favorites may not be the best way to score on Meme stocks, analysts say. Meme stock ETFs can help.

Investors Business Daily

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Benzinga

Stock Market Loses Ground For Second Day; Micron Warns; Coinbase Set To Report

Stock market indexes traded lower in the first hour of Tuesday's session, with chips and big tech taking the brunt of selling pressure. Energy stocks, led by natural gas plays, rose after Russian oil flows through central Europe were halted. The Dow Jones Industrial Average is trading lower by 0.2%…

Investors Business Daily

Dow Jones Falls As Inflation Report Looms; Covid Vaccine Maker Crashes On Earnings

The Dow Jones Industrial Average fell Tuesday ahead of Wednesday's key inflation report. Vaccine maker Novavax crashed on earnings results.

Investors Business Daily

Morning Digest | India finishes 4th as Commonwealth Games closes; BJP says it will stand by ally JD(U), and more

A select list of stories to read before you start your day

The Hindu

Read news from The Economist, FT, and more,
with one subscription

Novavax Stock Plummets As 'Market Dynamics' Crush Its 2022 Sales Outlook

Novavax widely missed second-quarter forecasts Tuesday, leading the Covid vaccine maker to slash its guidance and NVAX stock to crash.

Investors Business Daily

Dow Jones Futures: Market Rally Faces Key Inflation Report; Covid Vaccine Maker Crashes On Earnings

Dow Jones futures were lower after Monday's stock market action ahead of Wednesday's inflation report — the consumer price index.

Investors Business Daily

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

Benzinga

EU says Novavax COVID shot must carry heart side-effect warning

The European Medicines Agency (EMA) is recommending Novavax's COVID-19 vaccine carry a warning of the possibility of two types of heart inflammation, an added burden for a shot that has so far failed to win wide uptake.

Reuters

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

The CDC endorses Novavax, a more traditional COVID vaccine, for adults

Adults who haven't gotten any COVID-19 shots should consider the new option, the agency said Tuesday. The spike protein vaccine is more typical than the mRNA types being broadly used against COVID.

WEKU

Novavax COVID shot for adults gains CDC advisers’ backing

Novavax Inc.’s shares surged after its COVID-19 vaccine won backing from a panel of U.S. public health advisers, a crucial step in providing officials with another tool against the virus as cases start to rise again.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap of Tuesday's Biotech Catalysts - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

The Independent UK

CDC endorses new Novavax Covid vaccine

Two-dose shot will becomes fourth one to gain full approval later this week

The Independent UK

CDC advisers endorse more traditional Novavax COVID shot

Government advisers say U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax

StockNews.com

Is Novavax a Buy, Sell, or Hold Following FDA Decision?

Despite the FDA authorization of Novavax’s (NVAX) two-dose vaccine, the possible side effects and slow vaccine uptake keep the stock under pressure. So, let’s evaluate if it is worth adding the stock to one’s portfolio now. Read on….

Get all your
news in one place.

100’s of premium titles.
One news app.

ABC News

Australia has ordered millions more COVID vaccines than it needs. What are the options to deal with them?

Australia has used less than a quarter of the hundreds of millions of COVID-19 vaccine doses it bought. What will happen to the rest?

Benzinga

Novavax (NVAX) Down As EU Adds Side Effects To COVID Jab Label

Shares of Novavax (NASDAQ: NVAX) fell 26.2% on Jul 14, after the European Medicines Agency's (TSE: EMA) Pharmacovigilance Risk Assessment Committee ("PRAC") updated the product label of Nuvaxovid, the company's COVID-19 vaccine, to include some potential side effects like severe aller

Investors Business Daily

Stock Market Indexes Tumble Nearly 2% After Another Hot Inflation Report; Bank Earnings Disappoint

The producer price index jumped 11.3% in June from the same period a year ago.

Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Benzinga Before The Bell: Tesla's AI Exec Quits, Hyundai Unveils Ioniq 6 EV, Taiwan Semiconductor's Massive Q2 Profit Surge And Other Top Financial Stories Thursday, July 14

CNBC United Airlines, Pilots’ Union To Improve Agreement By Renegotiating

Tribune News Service

Novavax’s COVID vaccine gets US nod as latest pandemic weapon

Novavax Inc.’s COVID-19 vaccine was cleared by U.S. regulators, giving Americans another tool against the virus as cases start to rise again.

The Guardian - US

FDA authorizes protein-based Novavax Covid vaccine for adults

Approval of shot widens options against the virus as CDC will meet next week to decide whether to sign off on vaccine

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Bharatiya Janata Party

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.